Dr. Long is a physician, scientist, and medical researcher who develops new drugs. He joined the board of biomark Pharmaceuticals in 2004; he served as chairman from 2011 to 2014 and as CEO from 2013 to 2014. Dr. Long has worked in academia, large pharma, small pharma, and biotechnology companies.
Dr. Long’s most recent position (2008-2012) was chief medical officer and vice president of drug development at Biolex Therapeutics, where he had responsibility for preclinical and clinical development and later regulatory affairs. Prior to that he was vice president of clinical development at AtheroGenics Inc. (2005-2008), where he was responsible for clinical development and statistics and later regulatory affairs. From 1999 to 2005, he was senior vice president at Cato Research, where he was the senior medical and scientific officer for more than 100 projects. From 1993 to 1998, he was on the full-time faculty of the UNC School of Medicine, where he earned tenure. From 1983 to 1993, he held positions of increasing responsibility in clinical development at Burroughs Wellcome Co., and served on the part-time faculty of the UNC School of Medicine. Dr. Long has 217 publications including 71 peer-reviewed articles, six patents, and more than 100 invited national and international presentations at scientific and medical meetings.
Dr. Long’s accomplishments include the approvals of three first-in-class new chemical entities at three different FDA divisions. His research has resulted in a number of national and international awards including the Gold Pill Award and the Prix Galien.